Abstract
Background This study aimed to investigate actual tuberculosis (TB) risk and uptake rates of latent tuberculosis infection (LTBI) screening among eight clinical risk groups specified in Korean guidelines. Proportions of potentially preventable TB in these groups were also calculated.
Methods and Findings Patients enrolled before January 1st, 2018, were classified into a prevalence cohort whereas those enrolled thereafter were classified into an incidence cohort. Both cohorts were followed up until December 31st, 2020. Sex, age, and calendar year-adjusted standardized incidence ratio (SIR) of tuberculosis was calculated with total population in South Korea as a reference group. The number of TB patients notified in 2018 was investigated for both prevalence and incidence cohorts. SIR of TB in each incidence cohort was higher than that in each corresponding prevalence cohort. Among all incidence cohorts, SIR in people living with human immunodeficiency virus (PLHIV) was the highest (17.41, (95% CI: 14.14-21.43)). Although classified as moderate TB risk diseases in current guideline, end-stage renal disease (ESRD) (8.05, (7.02-9.23)) and uncontrolled diabetes mellitus (DM) (6.31, (5.78-6.99)) showed high SIRs comparable to other high-risk diseases. Among total TB cases notified in 2018, each cohort accounted for less than 1.5% except for patients with DM. The uptake rate of LTBI test was the highest among patients using TNF inhibitors (92.7%), followed by those who underwent organ transplantation (60.4%) and PLHIV (41.3%).
Conclusions LTBI screening should be reinforced for certain clinical risk groups such as ESRD or uncontrolled DM. Beyond the current guideline, additional high-risk groups should be identified.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Research Program funded by Korea Disease Control and Prevention Agency (2020E310100 to JSK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study protocol was reviewed and approved by the Institutional Review Board (IRB) of Incheon St. Mary's Hospital, the Catholic University of Korea (IRB No. OC20ZNDE0023). Informed consent from enrolled patients with high or moderate TB risk disease was waived due to the retrospective nature of this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data cannot be shared publicly, because personal information of Korean population in included in these datasets, which are protected under Personal Information Protection Act of South Korea. Korea Disease Control and Prevention Agency (KDCA) and National Health Insurance Service of Korea (NHIS) owns all datasets. The data used in the current study are available only after the permission from the KDCA and NHIS in advance.
